EIF2AK3 and neoplasm: Although the PERK small-molecule inhibitors, such as GSK2656157 and GSK2606414, have demonstrated good anti-tumour effects in mouse xenograft models (Atkins et al., 2013; Axten et al., 2012) and in combination treatments (Alasiri et al., 2019), their broader use as an anti-tumour drug has been hampered by their low efficacy as a single cytotoxic agent (Alasiri et al., 2019).